Pharmacoepidemiology and drug safety · 2026
Atypical Shoulder Pain and Dysfunction After Vaccinations Reported to the Vaccine Adverse Event Reporting System (VAERS) January 1, 2018, Through October 31, 2022.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miller Elaine R, Marquez Paige, Aynalem Getahun, Licata Charles, Rubin Mary Nythel, Freeborn Emma, Davis Shaeyla, Roberts Amy, Poudyal Manisha, Kim Sehwa S, Cooper Heather, Rounds Monica, Mozingo Liza, Amouzou Sandra, Zhang Bicheng, Dunbar Sara, Caraballo Valerie, Barre Aisha, McVey Rachel, Stibbe Caitlin, Harris Margaret, Davis Jennifer, Ramirez Vanessa, Lemperle Michael, Moro Pedro L
Аннотация
BACKGROUND: Shoulder injury related to vaccine administration (SIRVA) may result from improper vaccination technique when a vaccine is given into or near the subacromial bursa or synovium, which may result in shoulder pain, dysfunction, and long-lasting impairment.
METHODS: We searched the Vaccine Adverse Event Reporting System for reports received January 1, 2018, through October 31, 2022, describing atypical shoulder pain and dysfunction. We used the National Vaccine Injury Compensation Program's definition for SIRVA: onset within 48 h after vaccination, with pain and decreased range of motion in the vaccinated arm. We added the requirement that symptoms last ≥ 7 days.
RESULTS: Based on automated search, 26 061 (2.4%) were potential cases. In reviewing all 1819 serious and a random sample of 200 nonserious reports, 580 (32%) serious and 38 (19%) nonserious reports were potential SIRVA cases for a reporting rate of approximately 0.5%. SIRVA was rare in children and serious reports were most frequent among adult females (74%). A contributing factor was vaccine given "too high" in the arm in 68%. Interference/inability to perform activities of daily living and/or absenteeism from work was reported in 285 (64%) serious reports.
CONCLUSIONS: SIRVA is a rarely reported but important vaccine adverse event; symptoms can impact activities of daily living and work. Its greater frequency in female sex, rarity in children, and the association with the vaccine administered too high in the arm are consistent with previous studies. Prevention strategies should be prioritized, including vaccinator training to adhere to proper vaccine administration techniques.
METHODS: We searched the Vaccine Adverse Event Reporting System for reports received January 1, 2018, through October 31, 2022, describing atypical shoulder pain and dysfunction. We used the National Vaccine Injury Compensation Program's definition for SIRVA: onset within 48 h after vaccination, with pain and decreased range of motion in the vaccinated arm. We added the requirement that symptoms last ≥ 7 days.
RESULTS: Based on automated search, 26 061 (2.4%) were potential cases. In reviewing all 1819 serious and a random sample of 200 nonserious reports, 580 (32%) serious and 38 (19%) nonserious reports were potential SIRVA cases for a reporting rate of approximately 0.5%. SIRVA was rare in children and serious reports were most frequent among adult females (74%). A contributing factor was vaccine given "too high" in the arm in 68%. Interference/inability to perform activities of daily living and/or absenteeism from work was reported in 285 (64%) serious reports.
CONCLUSIONS: SIRVA is a rarely reported but important vaccine adverse event; symptoms can impact activities of daily living and work. Its greater frequency in female sex, rarity in children, and the association with the vaccine administered too high in the arm are consistent with previous studies. Prevention strategies should be prioritized, including vaccinator training to adhere to proper vaccine administration techniques.